Ladostigil therapy for immunomodulation
AssigneeYissum Research Development Company of the Hebrew University of Jerusalem
InventorMarta Weinstock-Rosin
Life of this patent
Estimating the term…
Abstract
Methods for treating individuals suffering from inflammation, specifically systemic inflammation including septic shock and inflammatory conditions affecting the gastrointestinal, myocardial and endocrine systems with ladostigil.
Claims4
A method for treating an inflammorory metabolic disease in a subject in need thereof, the method comprising administering a dail dose of 10 to 60 mg ladostigil or a pharmaceutically active salt thereof to a subject, thereby treating the disease in the subject, wherein the disease is selected from the group consisting of type 2 diabetes mellitus, type 1 diabetes mellitus, pre-diabetes, dyslipidemia, and insulin resistance, and the subject does not suffer from Alzheimer's disease or dementia, wherein said ladostigil is administered in an amount that inhibits no more than 15% acetylcholinesterase activity, monoamine oxidase activity, or the combined activities of both enzymes.
Dependencies are inferred from the claim text.